Activated T-cells (ATCs) combined with bispecific anti-CD3 x anti-Her2/neu antibodies (aATCs) effectively modulate MDSCs via INF and IL-2, suppressing their activity and inhibiting tumor growth (108). The gene discussed is ERBB2; the disease is neoplasm.